Advertisement
Canada markets closed

  • S&P/TSX

    21,728.55
    +14.01 (+0.06%)
     

  • S&P 500

    5,018.39
    -17.30 (-0.34%)
     

  • DOW

    37,903.29
    +87.37 (+0.23%)
     

  • CAD/USD

    0.7283
    +0.0022 (+0.30%)
     

  • CRUDE OIL

    79.13
    +0.13 (+0.16%)
     

  • Bitcoin CAD

    79,639.53
    -3,007.46 (-3.64%)
     

  • CMC Crypto 200

    1,202.07
    -136.99 (-10.23%)
     

  • GOLD FUTURES

    2,330.20
    +19.20 (+0.83%)
     

  • RUSSELL 2000

    1,980.23
    +6.32 (+0.32%)
     

  • 10-Yr Bond

    4.5950
    -0.0910 (-1.94%)
     

  • NASDAQ futures

    17,474.75
    -96.50 (-0.55%)
     

  • VOLATILITY

    15.39
    -0.26 (-1.66%)
     

  • FTSE

    8,121.24
    -22.89 (-0.28%)
     

  • NIKKEI 225

    38,274.05
    -131.61 (-0.34%)
     

  • CAD/EUR

    0.6791
    -0.0011 (-0.16%)
     

51job (JOBS) Looks Good: Stock Adds 6.6% in Session

Zacks Equity Research

51job, Inc. JOBS was a big mover last session, as the company saw its shares rises nearly 7% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock is down 14.7% in the past one-month time frame.

 

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

 

ADVERTISEMENT

51job currently carries a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

 

51job, Inc. Price

 

51job, Inc. Price
51job, Inc. Price

51job, Inc. price | 51job, Inc. Quote

A better-ranked stock in the broader Consumer Staples sector is SunOpta Inc. STKL, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

 

Breakout Biotech Stocks with Triple-Digit Profit Potential

 

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

 

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

 

See these 7 breakthrough stocks now>> 

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

51job currently carries a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

A better-ranked stock in the broader Consumer Staples sector is SunOpta Inc. (STKL), which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

 

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

 

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

 

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
SunOpta, Inc. (STKL) : Free Stock Analysis Report
 
51job, Inc. (JOBS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research